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Background: Porcine epidemic diarrhea virus (PEDV), a highly pathogenic and transmissible virus in swine, was first
detected in the U.S. in May, 2013, and has caused tremendous losses to the swine industry. Due to the difficulty in
isolating and growing this virus in cell culture, few vaccine studies using cell culture propagated PEDV have been
performed on U.S. strains in pigs. Therefore, the objective of this study was to evaluate the humoral immune
response to the selected inactivated PEDV vaccine candidate in a dose-titration manner.
Results: PEDV was isolated from a pig with diarrhea and complete genome sequencing found >99% nucleotide
identity to other U.S. PEDV. Inactivated adjuvanted monovalent vaccines were administered intramuscularly to five
week old pigs in a dose titration experimental design, ranging from 6.0-8.0 log10 tissue culture infective dose
(TCID50/mL), to evaluate immunogenicity using a fluorescent foci neutralization assay (FFN), fluorescent microsphere
immunoassay (FMIA), and enzyme-linked immunosorbent assay (ELISA) on sera. Pigs vaccinated with 8.0 log10
TCID50/mL inactivated virus showed significantly higher FFN titers as well as FMIA and ELISA values than 6.0 log10
TCID50/mL vaccinates and the negative controls.
Conclusions: These results demonstrate the immunogenicity of a PEDV inactivated viral vaccine with a U.S. strain
via dose-titration. A future vaccination-challenge study would illustrate the efficacy of an inactivated vaccine and
help evaluate protective FFN titers and ELISA and FMIA responses.
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Porcine epidemic diarrhea virus (PEDV) circulated
throughout Europe and Asia during the past three de-
cades before being detected in swine in the United States
in May, 2013 [1-7]. Since its introduction to the U.S.,
PEDV has been identified in 33 states by the National
Animal Health Laboratory Network, as of December,
2014 (www.aasv.org). It is characterized by watery diar-
rhea, vomiting, dehydration, and high mortality rates in
suckling pigs [8-10]. The U.S. PEDV strains are phylo-
genetically subgroup IIa, which is similar to PEDV circu-
lating in Asia in 2011 and 2012 [6,7].* Correspondence: rbatman@newportlabs.com; bhause@vet.k-state.edu
1Newport Laboratories Inc., Worthington, MN, USA
Full list of author information is available at the end of the article
© 2015 Collin et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Modified-live vaccines (MLVs) have long been used in
Asia for the control of PEDV [11-13]. The strain 83P-5,
attenuated by one-hundred cell culture passages, is a
subgroup I isolate that has been licensed in Japan as an
attenuated live PEDV vaccine [13]. During the attenu-
ation process, this strain acquired fourteen amino acid
changes in the immunodominant spike (S) protein,
which is critical for virus binding to cell receptors and is
the target of neutralizing antibodies [14-19]. The live at-
tenuated DR13 vaccine strain of PEDV, whose parent
strain was a subgroup II had thirteen of these fourteen
mutations as well, and subsequently clustered with sub-
group I [13]. Serial passage of 83P-5 in Vero cells re-
sulted in attenuation of virulence in vivo and the stronghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these phenotypic changes.
Classically attenuated cell culture passaged PEDV also
shows mutations in open reading frame 3 (ORF) and
changes to restriction fragment length polymorphism
(RFLP) cut patterns, which have been used to distinguish
MLV from field strains [10,20]. In vivo, high-passage
(x > 100) MLVs were attenuated in sows and piglets
while still capable of inducing a robust immune response
[20]. While attenuated in their ability to cause disease,
the safety of using MLV has been questioned, as MLV
are shed in the environment. Virus was detected in feces
of 3-day old piglets up to seven days after oral inocula-
tion with DR13 passage 100 [12,21] . In 2010, PEDV was
isolated from diarrheic pigs in China that had a close
phylogenetic relationship to two MLV vaccines, suggest-
ing it may have evolved from a MLV [22].
While modified live vaccines generally elicit a more ro-
bust and protective immune response than inactivated
virus vaccines [13], long-term efficacy is often lacking
due to viral mutations and accompanying antigenic
changes [23]. In late 2010, China experienced a severe
outbreak of PEDV in suckling pigs, causing drastic eco-
nomic losses [24]. This outbreak was caused by a strain
with a phylogenetically distinct S gene from other Chin-
ese strains and from vaccine strain CV777 [24]. In 2012,
the PEDV infection rates in vaccinated herds in China
increased dramatically. Phylogenetic analysis of new var-
iants from the outbreak showed insertions and deletions
in antigenic regions of the S gene that may have influ-
enced the efficacy of the CV777 MLV [25]. Investigation
into whether an inactivated vaccine can elicit a protect-
ive immune response could lead to the development of
vaccines more closely related to field strains and avoid
potential antigenic changes due to excessive in vitro
cultivation.
There are currently two conditionally licensed PEDV
vaccines in the U.S, with label claims for use in sows; an
inactivated virus vaccine and an alphavirus vectored sub-
unit vaccine. With mortality rates as high as 100% in
suckling piglets and total losses estimated over 5 million
animals in the U.S. in less than one year, PEDV vaccines
are critically needed (www.aasv.org). The U.S. Depart-
ment of Agriculture (USDA) allows for the production
of autogenous vaccines to address emerging diseases;
however the difficulty in isolating PEDV in cell culture
increases the difficulty in producing efficacious inacti-
vated vaccines. Here, PEDV was isolated from pooled in-
testinal homogenate and passaged in cell culture.
Inactivated cell culture derived viral vaccines were im-
munogenic when administered to naïve pigs. To our
knowledge, this is the first demonstration of immuno-
genicity of an inactivated U.S. PEDV vaccine trial in pigs
in the U.S.Methods
Ethics statement
Swine studies were performed at Newport Laboratories
and were approved by the Newport Laboratories’ Institu-
tional Animal Care and Use Committee.
Virus isolation
In May, 2013, intestines from pigs in Iowa experiencing
PEDV-like symptoms were submitted to Newport La-
boratories for diagnostic testing. Intestines were homog-
enized in phosphate buffered saline and debris was
removed by centrifugation at 10,000 × g for 10 minutes
followed by filtration through a 0.2 μm filter. Virus isola-
tion was performed on Vero (ATCC® CCL-81™), Vero 76
(ATCC® CRL-1586™), and MARC-145 (M145) cells [26].
All cells were maintained in Dulbecco’s modification of
Eagles medium (DMEM) with five percent fetal bovine
serum and one percent L-glutamine. Confluent mono-
layers were washed three times with DMEM without
serum prior to inoculation. For the initial infection of
cells in 12-well plates, 200 μL of inoculum was adsorbed
at 37°C with + 5% CO2 for 1–2 hours with small amount
of viral growth media (DMEM with 0.75 μg/mL ), L-1-
Tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-
treated trypsin, and Normocin™ antibiotic (Invivogen)).
The inoculum was rinsed from the plates with viral
growth media and the cells were refed with viral growth
media. Plates were incubated up to 5 days before being
frozen, thawed, and passaged. Subsequent passages were
performed by inoculating 200 μL of cell culture harvest
onto confluent monolayers in 12-well plates. Viral repli-
cation was verified by Real time reverse transcription
polymerase chain reaction (rt-RT-PCR) (below) and in-
direct immunofluorescence (IFA). Viral cultures were
scaled up in M145 25 cm2 flasks and 1700 cm2 roller
bottles, resulting in NPL PEDV 2013 P10.1PEDV.
Indirect immunofluorescence
IFA was performed on Vero or M145 96-well mono-
layers. Infected wells were fixed in cold ethyl alcohol
and polyclonal rabbit anti-PEDV nucleoprotein (NP)
antiserum (South Dakota State University Animal Dis-
ease Research and Diagnostic Laboratory (SDSU)) was
added at 1:500. Cells were rinsed and then incubated
with fluorescein isothiocyanate (FITC) labeled goat anti-
rabbit IgG (Jackson Immunoresearch) at a dilution of
1:50, and then read using a fluorescent microscope. Tis-
sue culture infective dose (TCID50/mL) was calculated
using the Spearman-Karber method.
Molecular analysis
Viral RNA from cell culture passages was extracted by
using the MagMAX™-96 viral RNA isolation kit (Life Tech-
nologies) according to the manufacturer’s instructions. rt-
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RT-PCR with the following PEDV primers and probe:
PEDV forward: 5’-ACG TCC GTA ACA CCT TCA AG
-3’, PEDV reverse: 5’-GCT AGT GCC TGT ACC ATA
GAT C-3’, and PEDV Probe: 5'-/5HEX/ CGT GCC AGT
AAT CAA CTC ACC CTT TGT /3IABkFQ/-3'. For ana-
lytical purposes, negative samples were assigned a Ct value
of 37.1, which corresponds to the detection limit of the
method (approximately −1.0 TCID50/mL). Method specifi-
city was assessed by using various porcine enteric viruses,
including transmissible gastroenteritis virus, group A rota-
virus and porcine enterovirus, and no cross-reaction was
observed. A standard curve was generated by serial dilu-
tion of M145 cell harvests containing 5.7 log10 TCID50/mL
of PEDV, as determined by titration on M145 cells.
RNA isolation for next generation sequencing
M145 cells that showed 100% cytopathic effects (CPE)
following virus infection at passage x + 9 were used for
RNA extraction for sequencing. 20 mL of cell culture
supernatant was filtered using the 0.2 μm bottle top fil-
ters (Thermo Scientific, Lenexa, Kansas). The filtrate
was centrifuged at 50,000 × g for 2 hours. Supernatant
was discarded and the pellet was suspended in 1000 μL
of water. Samples were concentrated to a final 100 μL
volume using Amicon® ultra centrifugal filters (0.5 mL;
50KDa) (Millipore, Tullagreen, Ireland). Cellular DNA
and RNA were removed by incubation with DNase I (25
units) (New England Biolabs, NEB, Ipswich, MA) and
RNase A (25units) (Qiagen, Valencia, CA) at 37°C for
1 hour. RNA was extracted using Trizol® LS Reagent
(Life Technologies, Grand Island, NY) according to
manufacturer’s instructions. The pellet containing RNA
was resuspended in 20 μL of sterile H2O.
Sequencing and data analysis
10 μg of total RNA was depleted of ribosomal RNA
using GeneRead™ rRNA depletion kit (Qiagen) and RNA
sequencing libraries were generated using the Ion Total
RNA-seq kit v2 (Ion Torrent™, Life Technologies) ac-
cording to manufacturer’s instructions. Sequencing was
carried out using Ion Personal Genome Machine®
(PGM) sequencing platform (Life Technologies, Grand
Island, NY) as previously described [27]. Sequence reads
were assembled into contigs using the SeqMan® NGen
program (DNAstar, Madison, WI). Phylogenetic analysis
on full genome sequences was performed using MEGA™
6.0 software using Maximum Likelihood analysis with
1000 bootstrap replicates to verify tree topology. Se-
quence alignments were performed using the ClustalW
algorithm in MegAlign (DNAstar, Madison WI). The
complete genome of NPL PEDV 2013 P10.1 was com-
pared to the sequence derived from the original clinical
sample [Genbank:KJ778615] and various referencestrains. The reference strains included: CV777 [Gen-
bank:EF353511] from Belgium; DR13 attenuated [Gen-
bank:JQ023162], DR13 virulent [Genbank:JQ023161],
and SM98 [Genbank:GU937797] from South Korea;
LZC [Genbank:EF185992], JS2008 [Genbank:KC109141],
and CHS [Genbank:JN547228] from China; CO13 [Gen-
bank:KF272920], MN [Genbank:KF468752], and a vari-
ant strain OH851 [Genbank:KJ399978] from the United
States. The genome sequence for NPL PEDV 2013 P10.1
was deposited in GenBank under the accession number
KM052365 [Genbank:KM052365].
Assessment of immunogenicity in swine
Swine vaccination studies were approved by the Institu-
tional Biosafety Committee, under Institutional Animal
Care and Use Committee (IACUC) guidelines. The stud-
ies were performed at Newport Laboratories under bio-
safety level 1. Sixty pigs approximately 4 weeks of age
were obtained from a commercial high-health herd.
They were of mixed sexes of crossbred American
Yorkshire-Landrace-Duroc. Prior to study commence-
ment pigs were verified as serologically negative to
PEDV by FFN and IFA. Pigs were also negative for
PEDV shedding by rt-RT-PCR on fecal swabs. Pigs were
divided into 8 vaccination groups of 5–9 pigs and a non-
vaccinated control group of 5 pigs, co-mingled among
two different rooms. Pigs were allowed 1 week to accli-
mate prior to study commencement.
Virus NPL PEDV 2013 P10.1 (6.6 log10 TCID50/mL)
was inactivated and concentrated 30X for use as vaccine.
Inactivation was performed by the addition of 0.1 M bin-
ary ethyleneimine (BEI) to a final volume of 5% and
incubating at 37°C for 24 hours. Excess BEI was neutral-
ized with sodium thiosulfate. Virus inactivation was veri-
fied by passaging the inactivated fluids three times on
permissive cells, resulting in no evidence of CPE or in-
crease in rt-RT-PCR titer. Concentration was performed
using a 10kD hollow fiber filter (Spectrum Labs). Due to
the space constraints and the number of study groups,
vaccination groups receiving 8.0 log10 TCID50/mL anti-
gen consisted of more pigs than groups receiving lower
levels of antigen as they were anticipated to show the
most robust immune response (Table 1). Groups 1–3
were vaccinated intramuscularly (IM) in the neck with
2 mL of 8.0, 7.0 or 6.0 log10 TCID50/mL, respectively, of
inactivated virus. Groups 5–7 were vaccinated IM in the
neck with 2 mL of 8.0, 7.0 or 6.0 log10 TCID50/mL, re-
spectively, of inactivated virus treated with Triton® X-
100 (added to 0.1% and incubated at room temperature
30 minutes) (Sigma). Groups 4 and 8 were vaccinated in
the rear flank with 8.0 log10 TCID50/mL of inactivated
virus and inactivated virus treated with Triton® X-100,
respectively. This was done to evaluate any potential
changes in immune response due to a change in
Table 1 Vaccination groups and treatment
Group Vaccine* Pigs
0 Negative control 5
1 8.0 IM 8
2 7.0 IM 5
3 6.0 IM 5
4 8.0 RF 9
5 8.0 IM + Triton® X-100 9
6 7.0 IM + Triton® X-100 5
7 6.0 IM + Triton® X-100 5
8 8.0 RF + Triton® X-100 9
*PEDV titer in vaccine prior to inactivation (log10 TCID50/mL) and route of
administration (IM, intramuscular neck; RF, rear flank).
Collin et al. BMC Veterinary Research  (2015) 11:62 Page 4 of 9vaccination site. All vaccines were formulated to contain
67% TS6, a proprietary oil in water adjuvant. Pigs were
vaccinated on days 0 and 21 and observed for adverse
vaccine reactions for one hour. Animals were also ob-
served daily for signs of disease. Serum was collected on
days 0, 21 and 35, and the study was terminated at day
35. Fecal swabs were collected three days post vaccin-
ation and were tested by rt-RT-PCR to confirm absence
of PEDV shedding.
Serology
The fluorescent foci neutralization assay (FFN) was per-
formed at SDSU using a National Veterinary Services
Laboratory (NVSL) reference isolate, USA/Colorado/
2013 (CO/13). Briefly, test and control serum samples
were heat inactivated at 56°C for 30 minutes, then seri-
ally diluted in serum-free Modified Eagles Medium
(MEM) containing 1.0 μg/mL TPCK treated trypsin in
96-well plates with a final volume of 100 μL/well. Next,
100 μL of PEDV stock diluted to 100–200 fluorescent
focus units (FFU)/100 μL was added to each well and
plates were incubated at 37°C for 1 hour. Plates contain-
ing confluent 3 day old monolayers of Vero-76 cells
were washed 3 times with serum-free MEM prior to
transfer of the serum/virus mixtures to corresponding
wells of these plates. After 1 hour incubation at 37°C,
the serum/virus mixture was removed, monolayers
washed once with serum-free MEM and 150 μL/well re-
placement media (MEM with 1.0 μg/mL TPCK treated
trypsin) was added to each well. Plates were incubated
24 hours at 37°C, then monolayers fixed for 15 minutes
with 80% acetone in water, dried and stained with fluor-
escein conjugated PEDV anti-nucleoprotein (NP) mono-
clonal antibody SD6-29. Titers were reported as the
reciprocal of the greatest serum dilution resulting in a
90% or greater reduction in FFU relative to virus control
well. A FFN titer <20 was considered negative.
Enzyme-linked immunosorbent assay (ELISA) was per-
formed at the University of Minnesota (UMN) VeterinaryDiagnostic Laboratory. The assay utilizes a recombinant
PEDV NP antigen and samples with a sample to positive
ratio (S/P) value greater than 0.5 are considered positive.
An experimental ELISA using a recombinant PEDV NP
was also performed at SDSU to verify the UMN results.
The SDSU cutoff for positive results was an S/P of 0.4, ac-
cording to ROC analysis using Medcalc software (unpub-
lished conference proceedings). Both ELISAs detected
only swine IgG.
To further investigate the immune response to the
inactivated PEDV vaccine, a fluorescent microsphere im-
munoassay (FMIA) was performed at SDSU using the
same purified, full-length 51 kDa PEDV nucleoprotein
antigen used in the ELISA. Briefly, the full length nu-
cleocapsid open reading frame of PEDV was cloned into
the pET-28a prokaryotic expression vector (Novagen).
Recombinant proteins were expressed as His-tagged fu-
sion proteins and purified using Ni-NTA agarose col-
umn chromatography prior to fluorescent microsphere
coupling. The FMIA was performed as previously de-
scribed [28,29]. Coupled microspheres were analyzed
through a dual-laser Bio-Rad Bio-Plex 200 instrument.
The mean fluorescence intensity (MFI) for 100 micro-
spheres corresponding to each individual bead analyte
was recorded for each well. All reported MFI measure-
ments were normalized via F - F0, where F0 was the
background signal determined from the fluorescence
measurement of a test sample in uncoated beads and F
was the MFI for a serological test sample in antigen-
coated beads.
Statistical analysis
Statistical analysis was performed using SPSS 14 soft-
ware. One-way ANOVA and Tukey HSD was performed
on all groups, using harmonic mean sample size of 6.171
to account for unequal group sizes. Also, a comparison
between the groups that had the same titer of the virus
and different treatment was done by t-test.
Results
Virus isolation
The rt-RT-PCR Ct value of the PEDV positive intestinal
homogenate was 21.4. After initial isolation attempts on
Vero and Vero 76 cell lines, passaging of samples con-
tinued on Vero cells as viral replication was evident by
rt-RT-PCR. CPE was evident after two passages and con-
firmed as PEDV by rt-RT-PCR and IFA. The Ct values
for passages x + 1 through x + 5 ranged from 17.8-23.5.
Cultures were scaled to a T25 Vero flask for x + 6 (17.97
Ct, 4.4 log10 TCID50/mL). Cell cultures were adapted to
M145 cells at x + 7 (18.55 Ct, 4.4 log10 TCID50/mL) and
x + 8 (23.31 Ct and 5.2 TCID50/mL) due to their USDA-
licensed status for autogenous vaccine production. After
two passages in M145 25 cm2 flasks, the culture was
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passage, X + 9, had a Ct = 21.2 and a titer of 6.6 log10
TCID50/mL as determined by IFA. The isolated PEDV
was designated NPL PEDV 2013 P10.1.
Genetic analysis
Phylogenetic analysis of complete genome sequences
showed >99% identity to U.S. PEDV virus CO/13 [Gen-
bank:KF272920] and the original intestinal sample [Gen-
bank:KJ778615]. The Minnesota isolate [Genbank:KF
468752] and an isolate from Ohio [Genbank:KJ408801]
were also closely related to the NPL PEDV2013 strain
(Figure 1). The ORF1ab, S, ORF3, envelope (E), membrane
(M), and NP genes of eleven PED reference viruses were
aligned and the percent nucleotide identity to NPL
PEDV2013 P10.1 was determined (Table 2). ORF3 showed
the greatest divergence, with 93.1-100% nucleotide iden-
tity. The S gene was the next most divergent, with 93.5-
99.9% nucleotide identity. Amongst the US strains, ORF3,
E, M, and NP were highly conserved with greater than
99.8% nucleotide identity. The S gene showed the greatest
variability amongst U.S. strains, with OH851 having 96.9%
identity to NPL PEDV 2013 P10.1 [30].
Pig vaccination and serology
All pigs in the study were confirmed seronegative for
PEDV antibodies at day 0 by IFA and FFN (data not
shown). Pig fecal swabs collected on day 3 post vaccin-
ation were negative for PEDV, further confirming that
no infectious PEDV was present in the vaccine. No ad-
verse reactions were noted following vaccination on days
0 and 21.
All vaccine groups had positive mean titers by the
FFN (Table 3). Post Hoc analysis of the FFN results
showed that all 8.0 log10 TCID50/mL groups [1,4,5,8],
along with 7.0 log10 TCID50/mL Triton® X-100 treatedO
DR13 virulent (JQ0
CH.S (JN547
SM98 (GU
JS2008 (
9
10
100
100
89
100
0.005
Figure 1 Phylogenetic analysis of 12 full-length porcine epidemic dia
MEGA 6.0 software using Maximum Likelihood analysis with 1000 bootstrap
shown in parentheses. Bootstrap values are shown above and to the left ogroup (group 6), had statistically significant higher mean
FFN titers than the control group 0 at p = 0.05 level and
did not have a significant difference in means compared
to each other per Tukey HSD. No groups were statisti-
cally similar to the control group by Tukey HSD analysis
(using harmonic mean sample size of 6.171 due to un-
equal group sizes). The t-test was also performed on
groups that had the same titer of virus and different
treatment (Table 4). There was no statistical difference
in FFN titers between vaccination groups of the same
titer with and without Triton® X-100 treatment for the
FFN assay.
Only one of the 9 animals in group 8, the 8.0 log10
TCID50/mL of inactivated Triton® X-100 treated virus to
the rear flank, showed positive ELISA results at UMN
(data not shown). To further clarify these results, an
ELISA test was performed at SDSU and the results sup-
ported the UMN results in that no anti-nucleoprotein
antibody from the Triton® X-100 treated groups was rec-
ognized. The ELISA results showed highly significant in-
creases in S/P ratios in the 8.0 log10 TCID50/mL of
inactivated virus to the IM neck and rear flank (groups 1
and 4, respectively) compared to control group 0 for
both UMN and SDSU assays (Table 3). There was no
significance between groups 1 and 4 by Tukey HSD, but
both had significantly higher results compared to the
remaining groups for the UMN ELISA. For the SDSU
ELISA, group 2 (7.0 log10 TCID50/mL) also had signifi-
cantly higher results than groups 3, 5, 6, and 8, per
Tukey HSD. The t-test shows significant differences in
ELISA results for the 8.0 log10 TCID50/mL groups 1
and 5 (IM, with and without Triton® X-100, respect-
ively), as well as the 8.0 log10 TCID50/mL groups 4 and
8 (flank, with and without Triton® X-100, respectively).
Also, the SDSU ELISA showed near significant differ-
ence between the 7.0 log10 TCID50/mL groups 2 and 6NPL-PEDV 2013 P0 (KJ778615)
MN (KF468752)
NPL-PEDV 2013 P10.1 (KM052365)
CO13 (KF272920)
H851 (KJ399978)
23161)
228)
937797)
KC109141) 
SM98 (GU937797)
CV777 (AF353511)
LZC (EF185992)3
0
94
100
rrhea virus genomes. Phylogenetic analysis was performed using
replicates to verify tree topology. Genbank accession numbers are
f major nodes.
Table 2 Genogroup and percent nucleotide identity of reference porcine epidemic diarrhea viruses to NPL PEDV 2013
P10.1
Virus (accession number) Genogroup ORF 1ab S ORF3 E M NP
CHS (JN47228) G1 98.0 93.8 98.2 96.5 98.1 96.8
CO13 (KF272920) G2 100.0 99.9 99.9 100.0 100.0 100.0
CV777 (AF353511) G1 97.3 94.0 96.9 97.0 98.2 96.0
DR13 Attenuated (DQ462404) G1 97.8 93.6 93.1 96.7 97.9 96.8
DR13 Virulent (JQ023161) G2 98.2 95.0 98.5 98.3 98.4 97.4
JS2008 (KC109141) G1 98.0 94.2 93.1 96.1 97.8 96.8
LZC (EF185992) G1 97.2 93.5 95.6 96.1 97.2 95.8
MN (KJ468752) G2 99.8 99.7 100.0 100.0 100.0 100.0
OH851 (KJ399978) G2 99.5 96.9 100.0 100.0 99.9 99.8
SM98 (GU937797) G1 97.2 93.7 96.8 96.1 98.1 95.9
NPL PEDV2013 p0 (KJ778615) G2 100.0 99.8 100.0 100.0 100.0 100.0
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p value of 0.057.
FMIA was performed and groups 1, 2, and 4 (8.0 log10
TCID50/mL and 7.0 log10 TCID50/mL IM and 8.0 log10
TCID50/mL flank) and MFI values were significantly
higher than the control by Tukey HSD analysis (Table 3).
Again, the 8.0 log10 TCID50/mL vaccine groups and the
7.0 log10 TCID50/mL group without Triton® X-100 had
statistically higher MFI than the Triton® X-100 treated
groups by t-test (Table 4). Group 2, the 7.0 log10
TCID50/mL group, had statistically lower MFI than
groups 1 and 4, and significantly higher MFIs than all
other groups. The 6.0 log10 TCID50/mL groups [3,7]
MFI showed no difference in Triton® X-100 treatment
by t-test and were not significantly higher than controls
via Tukey HSD. This is probably due to low antibody ti-
ters at the 6.0 log10 TCID50/mL level. These results indi-
cate that the Triton® X-100 treatment created significant
differences in both ELISAs and the FMIA assay results,
but did not affect FFN results.
Discussion
The severity of disease caused by an outbreak of PEDV
makes it imperative that an efficacious vaccine be devel-
oped. Due to the difficulties of in vitro cultivation and
high virus transmissibility leading to biosecurity con-
cerns, limited research has been performed in pigs in
the U.S. With a four percent success rate for virus isola-
tion being reported, the development of diagnostic tests
and research of U.S. field strains has been hampered [6].
After successfully isolating and passaging a U.S. PEDV
isolate, growth was maintained on M145 cells between
5.0-6.6 TCID50/mL.
The genetic characterization of NPL PEDV2013 P10.1
found that it is 99% identical to the strains circulating in
Asia in the early 2010s. Its high genetic homology to the
other circulating strains in the U.S. makes it a suitablecandidate for investigation of U.S. PEDV inactivated vac-
cine immunogenicity in pigs. While there is data pub-
lished regarding the efficacy of attenuated MLVs in Asia,
there is limited published data on the immunogenicity
of inactivated or subunit PEDV vaccines. This study
demonstrates that inactivated PEDV vaccines are im-
munogenic is pigs.
Vaccine groups in this study were designed investigate
at the effects of virus titer, site of administration and de-
tergent treatment of antigen on immunogenicity in pigs.
A dose response was observed by FFN for vaccines con-
taining different virus titers, with 8.0 log10 TCID50/mL
groups all being significantly greater than 6.0 log10
TCID50/mL groups. Vaccines were administered IM or
in the rear flank to determine if the site of administra-
tion would affect overall immunogenic response. The
flank vaccination site was only tested on the 8.0 log10
TCID50/mL groups, as we expected them to have the
highest immune response; however there was no signifi-
cant difference between the two sites of administration.
Likewise, there was no significant difference between
vaccines formulated with Triton® X-100 treated antigen,
by FFN. A challenge model is needed to correlate FFN
and/or ELISA titers to protection.
Surprisingly, with the exception of one pig, negative
ELISA results were obtained from pigs vaccinated with
Triton® X-100 treated virus formulated at 8.0 log10
TCID50/mL despite high FFN mean titers. The t-test
shows Triton® X-100 treated groups were significantly
different from non- Triton® X-100 treated groups at the
same titer for ELISA and FMIA. Triton® X-100 detergent
is used to create split-virion vaccines of influenza virus
that are immunogenic and non-reactogenic [31]. Our
data suggests that Triton® X-100 treatment of the PEDV
antigen altered the antigenicity or immunogenicity of
the NP, leading to negative ELISA results, while other
immunogens capable of inducing a neutralizing antibody
Table 4 T-test comparison between groups with same
titer and different treatment (with and without Triton® X-
100 treatment), results considered significant at p <0.05
level
Group FFN UM ELISA SDSU ELISA FMIA
2,6 .356 .143 .057 .038
3,7 .727 .986 .305 .438
1,5 .657 .000 .000 .000
4,8 .466 .000 .000 .000
Table 3 One way Anova and Tukey HSD
Group FFNǂ UM ELISA# SDSU ELISA#§ FMIA£
0 (control) Mean 1.93 D 0.00B 0.05c 0.04C
N = 5 Std.Deviation 2.66 0.00 0.05 0.04
Std. Error 1.19 0.00 0.02 0.02
1 - 8.0 log10 TCID50/mL Mean 7.32
*A,B 1.06*A 1.79*A 1.14*A
N = 8 Std.Deviation 1.2 0.17 0.79 0.04
Std. Error 0.42 0.06 0.28 0.01
2 - 7.0 log10 TCID50/mL Mean 5.06
B,C 0.29B 0.57B 0.51*B
N = 5 Std.Deviation 3.24 0.39 0.54 0.42
Std. Error 1.45 0.17 0.24 0.19
3 - 6.0 log10 TCID50/mL Mean 4.66
C 0.01B 0.07C 0.08C
N = 5 Std.Deviation 2.74 0.02 0.04 0.07
Std. Error 1.23 0.01 0.02 0.03
4 - 8.0 log10 TCID50/mL (Flank) Mean 7.99
*A 1.04*A 2.11*A 1.16*A
N = 9 Std.Deviation 1.32 0.40 0.26 0.03
Std. Error 0.44 0.13 0.09 0.01
5 - 8.0 log10 TCID50/mL (Triton® X-100) Mean 6.99
*A,B 0.00B 0.04C 0.06C
N = 9 Std.Deviation 1.80 0.01 0.03 0.07
Std. Error 0.60 0.00 0.01 0.02
6 - 7.0 log10 TCID50/mL (Triton® X-100) Mean 6.52
*A,B,C 0.11B 0.03C 0.04C
N = 5 Std.Deviation 0.84 0.03 0.04 0.05
Std. Error 0.37 0.011 0.02 0.23
7 - 6.0 log10 TCID50/mL (Triton® X-100) Mean 5.12
B,C 0.01B 0.36C,B 0.14C
N = 5 Std.Deviation 0.84 0.02 0.59 0.13
Std. Error 0.37 0.01 0.27 0.06
8 - 8.0 log10 TCID50/mL (Triton® X-100, Flank) Mean 7.54
*A 0.14B 0.06C 0.02C
N = 9 Std.Deviation 1.20 0.41 0.45 0.03
Std. Error 0.40 0.14 0.02 0.11
A,B,C,D Tukey HSD lists different letters between groups whose means that are statistically significant. Those with same letters means no significant difference
among their means. Tukey HSD used harmonic mean sample size = 6.171 to account for differences in group sizes.
ǂThe FFN results were log2 transformed before analysis.
#The ELISA results are sample to positive (S/P) ratios. The UMN ELISA cutoff is 0.5. #§The SDSU cutoff for ELISA is S/P of 0.4.
£The FMIA MFI cutoff is 0.1.
*The mean difference is significant at the 0.05 level compared to the control group.
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The two ELISA tests and the FMIA all utilize NP anti-
gen. Triton® X-100 treatment of the vaccine may have al-
tered the conformation of the virion NP such that
antibody induced by this antigen was not able to
recognize the recombinant NP used in the ELISA or
FMIA. An assay, such as the FFN, that detects functional
neutralizing antibody associated with epitopes on the S
protein may be better at quantifying antibody response
to Triton® X-100 treated viruses. Few ELISAs targeting
the S protein are readily available and they may also be
subject to variations in protein conformation associated
with Triton® X-100 treatment.
Though the vaccine in this trial was able to generate
an antibody response, as indicated by FFN, FMIA, and
Collin et al. BMC Veterinary Research  (2015) 11:62 Page 8 of 9ELISA assays, a protective titer is unknown. Previous
work with attenuated virus used to vaccinate sows
showed an immune response by ELISA in serum and
colostrum, but could not draw a specific correlation to
the level of mucosal immunity needed to confer protec-
tion [32]. Another study showed antibody was detected
in serum from piglets and colostrum from pregnant
sows after being inoculated with attenuated PEDV,
though finding a specific protective antibody titer of the
colostrum was complicated due to varying factors in-
cluding litter size, colostrum uptake per piglet, antibody
concentration, and quality of colostrum [20]. Due to bio-
security concerns, a post-vaccination challenge was not
performed for this study. This should be done in the fu-
ture to determine immune correlates of protection.
With reports that farms can be re-infected after a pri-
mary outbreak, disease will continue to be an ongoing
problem due to lack of complete immunity after infection.
In one case, piglets born from re-infected sows were re-
ported to suffer around 30% mortality instead of near
100% during the first outbreak [33]. Further research is
necessary to determine if secondary outbreaks in sows
could be prevented via vaccination and or boosters. While
this study focused on the humoral immune response in
sera from vaccinated pigs, the post-vaccination immune
response in sows and antibody titers in colostrum should
be studied as the optimal vaccination regimen would
utilize maternal antibodies to protect pigs when they are
most susceptible to PEDV. Additionally, inactivated vac-
cines may prove efficacious when used as a booster in
conjunction with live exposure or following MLV. If there
is risk of re-infection among previously exposed herds, an
inactivated vaccine booster to pregnant sows could reduce
the occurrence of re-infection and limit secondary out-
breaks. PEDV continues to be a source of economic loss
and will continue to have a profound impact on the swine
market in the U.S.
Conclusions
These results demonstrate the immunogenicity of the
PEDV inactivated viral vaccines with a U.S. strain. Infor-
mation from this immunogenicity study shows the po-
tential for inactivated vaccine development for U.S.
PEDV strains. Further work is needed to evaluate pro-
tective FFN titers and ELISA and FMIA responses in a
vaccination-challenge study.
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